DMK PHARMACEUTICALS CORPORATION Income (Loss) from Continuing Operations, Per Basic and Diluted Share
DMK PHARMACEUTICALS CORPORATION reported Income (Loss) from Continuing Operations, Per Basic and Diluted Share of -$0.24 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare · last filed 2022-03-31
- DMK PHARMACEUTICALS CORPORATION income (loss) from continuing operations, per basic and diluted share for the quarter ending 2021-09-30 was -$0.03.
- DMK PHARMACEUTICALS CORPORATION income (loss) from continuing operations, per basic and diluted share for the quarter ending 2020-09-30 was -$0.13.
- DMK PHARMACEUTICALS CORPORATION income (loss) from continuing operations, per basic and diluted share for fiscal 2021 was -$0.24.
- DMK PHARMACEUTICALS CORPORATION income (loss) from continuing operations, per basic and diluted share for fiscal 2020 was -$0.46.
- DMK PHARMACEUTICALS CORPORATION income (loss) from continuing operations, per basic and diluted share for fiscal 2013 was -$0.07.
- DMK PHARMACEUTICALS CORPORATION income (loss) from continuing operations, per basic and diluted share for fiscal 2012 was -$0.06.
| Period end | Income (Loss) from Continuing Operations, Per Basic and Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Basic and Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Basic and Diluted Share 12 month |
|---|---|---|---|
| 2021-12-31 | -$0.24 10-K · filed 2022-03-31 | ||
| 2021-09-30 | -$0.03 10-Q · filed 2021-11-22 | -$0.19 10-Q · filed 2021-11-22 | |
| 2020-12-31 | -$0.46 10-K · filed 2022-03-31 | ||
| 2020-09-30 | -$0.13 10-Q · filed 2021-11-22 | -$0.33 10-Q · filed 2021-11-22 | |
| 2013-03-31 | -$0.07 10-K · filed 2013-07-03 | ||
| 2012-03-31 | -$0.06 10-K · filed 2013-07-03 | ||
| 2011-03-31 | -$0.11 10-K · filed 2012-06-29 |